A pilot study of idiotypic vaccination for follicular B-cell lymphoma using a genetic approach. CRC NO: 92/33. Protocol NO: PH1/027.
Hawkins
R E
RE
Russell
S J
SJ
Marcus
R
R
Ashworth
L J
LJ
Brissnik
J
J
Zhang
J
J
Winter
G
G
Bleehen
N M
NM
Shaw
M M
MM
Williamson
L
L
Ouwehand
W
W
Stevenson
F
F
Hamblin
T
T
Oscier
D
D
Zhu
D
D
King
C
C
Kumar
S
S
Thompsett
A
A
Stevenson
G T
GT
D000888:Antibodies, Anti-Idiotypic; D002985:Clinical Protocols; D017321:Clinical Trials, Phase I as Topic; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007135:Immunoglobulin Variable Region / Q000235:genetics* / Q000276:immunology; D007167:Immunotherapy / Q000009:adverse effects / Q000379:methods*; D007273:Injections, Intramuscular; D016393:Lymphoma, B-Cell / Q000276:immunology / Q000628:therapy; D008224:Lymphoma, Follicular / Q000276:immunology* / Q000628:therapy*; D008297:Male; D010865:Pilot Projects; D011994:Recombinant Proteins / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*
D000888:Antibodies, Anti-Idiotypic; D007135:Immunoglobulin Variable Region; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic